GlassScriptPhysician profile
Jennifer B Morgan
NPI 1558456434
$3,280.89
in general payments reported to CMS, 2019-2025
38 companies · $419 in 2025
The $419 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $120 · 2021: $343 · 2022: $920 · 2023: $799 · 2024: $256 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.96 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.47 | 2019-2024 | Liletta, Lo Loestrin Fe, Orilissa |
| Novo Nordisk INC | $475.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $263.45 | 2020-2025 | Veozah |
| Exeltis, USA INC. | $244.90 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $202.91 | 2019-2023 | |
| Axonics, INC. | $184.40 | 2022-2024 | Axonics |
| Mayne Pharma Commercial LLC | $140.26 | 2022-2025 | |
| Allergan, INC. | $129.38 | 2019-2020 | |
| Medtronic, INC. | $113.59 | 2022-2024 | Plasmablade(Tm) |
| Pfizer INC. | $110.17 | 2019-2025 | |
| Shield Therapeutics INC | $82.34 | 2022-2023 | Accrufer |
| Biogen, INC. | $77.00 | 2025 | Zurzuvae |
| Organon LLC | $76.86 | 2024-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $51.74 | 2020-2023 | Aptima |
| Amgen INC. | $48.79 | 2019-2024 | Prolia, Evenity |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $47.80 | 2021-2022 | |
| Applied Medical Resources Corporation | $32.17 | 2023 | |
| Therapeuticsmd, INC. | $31.91 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.31 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $27.37 | 2019 | |
| Lupin INC. | $26.68 | 2019 | |
| Agile Therapeutics, INC. | $24.57 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.10 | 2022 | |
| Ethicon US, LLC | $21.88 | 2023 | Enseal, Ethicon |
| Myovant Sciences INC. | $18.81 | 2022 | |
| Sumitomo Pharma America, INC. | $16.73 | 2023 | Myfembree |
| Idorsia Pharmaceuticals US INC | $16.20 | 2023 | Quviviq |
| Roche Diagnostics Corporation | $16.06 | 2019 | |
| Boston Scientific Corporation | $14.79 | 2023 | Solyx Sis System |
| Kvk-Tech, INC. | $14.47 | 2019 | |
| Exact Sciences Corporation | $14.35 | 2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $13.12 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.75 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.21 | 2019 | |
| Merck Sharp & Dohme LLC | $11.76 | 2020 | |
| Becton, Dickinson and Company | $11.64 | 2022 | |
| Meditrina | $8.37 | 2025 | |
| Channel Medsystems, INC. | $5.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.